FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2258266017> ?p ?o ?g. }

• W2258266017 endingPage "1036" @default.
• W2258266017 startingPage "1036" @default.
• W2258266017 abstract "1036 Background: E2100 was an open-label, multi-center, randomized, Phase III trial comparing P to P+B as initial chemotherapy for MBC. The original analysis based on investigator-assessed progression found a significant improvement in PFS (HR 0.498, p <0.001) (K. Miller, PASCO '05). A retrospective independent review of blinded radiological and clinical data was conducted to confirm the results. Methods: Radiographic images and physical exam findings were provided to the independent review facility (IRF; RadPharm Inc.) who reviewed these data in a blinded fashion, in accordance with a prespecified IRF charter following the RECIST criteria. PFS was reanalyzed as an intent-to-treat analysis of all 722 randomized subjects, and included on-study deaths and progression events assessed by the IRF that occurred on or before Feb 9, 2005 (consistent with the data cut-off for the original interim analysis). PFS was also reanalyzed using investigator assessments but otherwise following the same analysis methods. Results: Images were submitted for review for 89.9% of patients. Missing data were balanced between the two treatment arms. Eight planned sensitivity analyses that tested the impact of non-protocol therapy, missing data, and informative censoring in the assessment of progression for individual patients were conducted; all retained statistical significance for the addition of bevacizumab. Conclusions: The PFS risk was reduced by more than half and the ORR more than doubled with the addition of bevacizumab to weekly paclitaxel in both analyses, confirming the substantial and robust bevacizumab treatment effect. The strong consistency of the IRF and Investigator based PFS and ORR results validate original data reported by ECOG in this open-label trial. IRF Assessed Investigator Assessed P N=354 P+B N=368 P N=354 P+B N=368 Progression-free survival (HR) 0.483 0.421 p value (log-rank) <0.0001 <0.0001 Median (months) 5.8 11.3 5.8 11.4 Objective response in patients with measurable disease at baseline (%) 22.2 49.8 23.4 48.0 p value <0.0001 <0.0001 HR=hazard ratio Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Genentech, Inc. Genentech, Inc., Roche Amgen, Genentech, Inc., Gilead Sciences Genentech, Inc. Genentech, Inc." @default.
• W2258266017 created "2016-06-24" @default.
• W2258266017 creator A5025364402 @default.
• W2258266017 creator A5036015012 @default.
• W2258266017 creator A5037428122 @default.
• W2258266017 creator A5043219897 @default.
• W2258266017 creator A5044143691 @default.
• W2258266017 creator A5063856811 @default.
• W2258266017 creator A5065306642 @default.
• W2258266017 creator A5068666503 @default.
• W2258266017 creator A5069795948 @default.
• W2258266017 creator A5080593577 @default.
• W2258266017 date "2008-05-20" @default.
• W2258266017 modified "2023-09-24" @default.
• W2258266017 title "Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC)" @default.
• W2258266017 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.1036" @default.
• W2258266017 hasPublicationYear "2008" @default.
• W2258266017 type Work @default.
• W2258266017 sameAs 2258266017 @default.
• W2258266017 citedByCount "11" @default.
• W2258266017 countsByYear W22582660172012 @default.
• W2258266017 countsByYear W22582660172021 @default.
• W2258266017 crossrefType "journal-article" @default.
• W2258266017 hasAuthorship W2258266017A5025364402 @default.
• W2258266017 hasAuthorship W2258266017A5036015012 @default.
• W2258266017 hasAuthorship W2258266017A5037428122 @default.
• W2258266017 hasAuthorship W2258266017A5043219897 @default.
• W2258266017 hasAuthorship W2258266017A5044143691 @default.
• W2258266017 hasAuthorship W2258266017A5063856811 @default.
• W2258266017 hasAuthorship W2258266017A5065306642 @default.
• W2258266017 hasAuthorship W2258266017A5068666503 @default.
• W2258266017 hasAuthorship W2258266017A5069795948 @default.
• W2258266017 hasAuthorship W2258266017A5080593577 @default.
• W2258266017 hasConcept C121608353 @default.
• W2258266017 hasConcept C126322002 @default.
• W2258266017 hasConcept C141071460 @default.
• W2258266017 hasConcept C143998085 @default.
• W2258266017 hasConcept C168563851 @default.
• W2258266017 hasConcept C2775930923 @default.
• W2258266017 hasConcept C2776694085 @default.
• W2258266017 hasConcept C2777802072 @default.
• W2258266017 hasConcept C2780739268 @default.
• W2258266017 hasConcept C530470458 @default.
• W2258266017 hasConcept C61943457 @default.
• W2258266017 hasConcept C65409693 @default.
• W2258266017 hasConcept C71924100 @default.
• W2258266017 hasConceptScore W2258266017C121608353 @default.
• W2258266017 hasConceptScore W2258266017C126322002 @default.
• W2258266017 hasConceptScore W2258266017C141071460 @default.
• W2258266017 hasConceptScore W2258266017C143998085 @default.
• W2258266017 hasConceptScore W2258266017C168563851 @default.
• W2258266017 hasConceptScore W2258266017C2775930923 @default.
• W2258266017 hasConceptScore W2258266017C2776694085 @default.
• W2258266017 hasConceptScore W2258266017C2777802072 @default.
• W2258266017 hasConceptScore W2258266017C2780739268 @default.
• W2258266017 hasConceptScore W2258266017C530470458 @default.
• W2258266017 hasConceptScore W2258266017C61943457 @default.
• W2258266017 hasConceptScore W2258266017C65409693 @default.
• W2258266017 hasConceptScore W2258266017C71924100 @default.
• W2258266017 hasIssue "15_suppl" @default.
• W2258266017 hasLocation W22582660171 @default.
• W2258266017 hasOpenAccess W2258266017 @default.
• W2258266017 hasPrimaryLocation W22582660171 @default.
• W2258266017 hasRelatedWork W144521535 @default.
• W2258266017 hasRelatedWork W2023654245 @default.
• W2258266017 hasRelatedWork W2037317309 @default.
• W2258266017 hasRelatedWork W2077649377 @default.
• W2258266017 hasRelatedWork W2258266017 @default.
• W2258266017 hasRelatedWork W2411890706 @default.
• W2258266017 hasRelatedWork W2782589310 @default.
• W2258266017 hasRelatedWork W2891273047 @default.
• W2258266017 hasRelatedWork W3026121525 @default.
• W2258266017 hasRelatedWork W3029647642 @default.
• W2258266017 hasVolume "26" @default.
• W2258266017 isParatext "false" @default.
• W2258266017 isRetracted "false" @default.
• W2258266017 magId "2258266017" @default.
• W2258266017 workType "article" @default.